Close Menu

NEW YORK (GenomeWeb) – Cancer informatics and precision medicine firm Tempus said today that it has raised $110 million in a Series E financing round.

Participants in the round included Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates, and other existing investors.

Tempus, based in Chicago, said that it will use the additional funds to grow operations and expand into new therapeutic areas and geographies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.